Overall, TAVI has become a viable option for selected high-risk patients with severe symptomatic pure native AR and has now been incorporated into contemporary guidelines in this setting.
Joao Matteo Rampone, Samuele Sandrone, S. Capoccia et al.· Reviews in cardiovascular me...· 0 citations
In severe aortic stenosis (AS) treated with transcatheter aortic valve implantation (TAVI), prognosis is strongly influenced by the extent of secondary cardiac damage, but echocardiographic staging is time- and resource-intensive and not universally available.
We aimed to evaluate whether an AI-enhanced 12...
J. Rampone, F. Bruno, O. de Filippo et al.· European Heart Journal· 0 citations
BACKGROUND
Anakinra is effective in recurrent pericarditis, yet optimal treatment duration and strategies for safe drug discontinuation remain uncertain. Identifying predictors of sustained remission after discontinuation is important for clinical management.
METHODS
We retrospectively analyzed 185 consecutive adult...
Danilo Malandrino, Alessandra Bettiol, A. Andreis et al.· Journal of the American Hear...· 0 citations
Genotype positivity in HCM links to earlier onset and family history; traditional severity markers and initial presentation may not independently suggest genetic causality, which may help shaping a personalized approach to genetic counseling in HCM.
F. Juvenal, F. Angelini, V. Dusi et al.· European Heart Journal· 0 citations
GLP-1 receptor agonists (GLP-1a) are a novel class of cardiometabolic drugs that have been shown to reduce the risk of major adverse cardiovascular events (MACE) and cardiovascular mortality in patients with type 2 diabetes, overweight, or obesity. Improved outcomes have also been reported in patients undergoing...
F. Giacobbe, A. Dalu, M. Balducci et al.· European Heart Journal· 0 citations
AI-based diagnostic algorithms for AMI diagnosis were associated with particularly efficient performance and has the potential to enhance existing tools by identifying subtle ECG features and integrating multiple data streams.
F. Giacobbe, O. de Filippo, M. Petracca et al.· Cardiovascular Research· 0 citations
BACKGROUND
Despite continuous advancements in devices and techniques, transcatheter aortic valve implantation remains associated with complications impacting outcomes. In 2021, the Valve Academic Research Consortium (VARC) introduced the VARC-3 criteria to better classify procedural complications.
METHODS
We conducte...
F. Giacobbe, Francesco Bruno, M. Brero et al.· Journal of the American Hear...· 0 citations
In contemporary European practice, patients <50 yrs undergoing LVAD implant had high 5-yr survival approaching that reported in cohorts of patients listed for HT, which support further investigation of prolonged LVAD support before HT as a potential strategy to maximize lifetime benefit in selected motivated younger ca...
G. Gallone, K. Veen, A. Bernhardt et al.· European Journal of Cardio-T...· 0 citations
BACKGROUND
The Venous Excess Ultrasound (VExUS) score is increasingly used to assess systemic venous congestion, yet direct validation against invasively measured right atrial pressure (RAP) in pulmonary hypertension (PH) remains limited.
RESEARCH QUESTION
How accurate is the VExUS score to predict RAP in patients wi...
M. D'Alto, N. Cangiano, Antonio Orlando et al.· Chest· 0 citations
Vericiguat reduces cardiovascular death and heart failure (HF) hospitalization in high-risk patients with HF and reduced ejection fraction (HFrEF), but its non-invasive haemodynamic and remodelling effects in real-world practice remain incompletely characterized. We aimed to evaluate changes in non-invasive hemodynamic...
P. Bocchino, C. Carbonaro, G. Gallone et al.· American Journal of Cardiolo...· 1 citation
The addition of evolocumab reduced the total number of MACE, providing support for the role of intensive low-density lipoprotein cholesterol lowering to prevent first and subsequent MACE in patients at high cardiovascular risk and no prior MI or stroke.
José C. Nicolau, S. Murphy, Robert P. Giugliano et al.· Journal of the American Coll...· 1 citation
These results support using evolocumab to improve survival in high-risk patients who have not experienced a previous myocardial infarction or stroke, including those with high-risk diabetes without qualifying atherosclerosis with low-density lipoprotein-cholesterol ≥ 90 mg/dl or apolipoprotein B ≥ 80 mg/dl.
Robert P. Giugliano, E. Bohula, A. Bellavia et al.· Circulation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.